REVVITY, INC. (RVTY): Results of Operations and Financial Condition
REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE August 4, 2026 Revvity Announces Financial Results for the Second Quarter of 2026 • Revenue of $730 million; pro forma revenue of $711 million; 4% pro forma revenue growth; 3% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.48 ;
How this was made
The 30-second read
Why it matters
The combination of a Q2 beat versus expectations (management commentary), a raised full-year pro forma EPS and revenue outlook, and a definitive China divestiture agreement creates two tradable drivers: near-term earnings/guidance positioning and longer-dated execution/regulatory risk.
Market read
This is a primary earnings-and-guidance update plus a definitive strategic divestiture disclosure, both of which can reprice the stock and change forward estimates.
What to watch
Traders should monitor how the company defines and reconciles pro forma versus GAAP going forward, and whether regulatory approvals for the China IDX divestiture introduce delays or conditions that affect 2027 earnings power.
Revvity Announces Financial Results for the Second Quarter of 2026
Pro forma revenue growth was 4%, pro forma organic revenue growth was 3%, and pro forma adjusted EPS increased to $1.41 from $1.15. Diagnostics delivered 12% pro forma revenue growth and expanded adjusted operating margin, while Life Sciences declined and tariff-related refunds contributed to operating income and adjusted EPS.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $ 729,688 | – | – |
| Pro forma revenueGAAP | $ 711,109 | – | 4% pro forma revenue growth |
| Pro forma organic revenue growthnon-GAAP | 3% | – | – |
| Cost of revenueGAAP | 312,822 | – | – |
| Pro forma cost of revenueGAAP | 302,876 | – | – |
| Selling, general and administrative expensesGAAP | 278,576 | – | – |
| Pro forma selling, general and administrative expensesGAAP | 265,739 | – | – |
| Research and development expensesGAAP | 48,974 | – | – |
| Pro forma research and development expensesGAAP | 48,798 | – | – |
| Operating income from continuing operationsGAAP | 89,316 | – | – |
| Pro forma operating income from continuing operationsGAAP | 93,696 | – | – |
| GAAP operating profit margin from continuing operationsGAAP | 12.2% as a percentage of revenue | – | – |
| Pro forma operating profit marginGAAP | 13.2% as a percentage of pro forma revenue | – | – |
| Adjusted operating incomenon-GAAP | $211 million | – | – |
| Pro forma adjusted operating incomenon-GAAP | $209 million | – | – |
| Adjusted operating profit marginnon-GAAP | 28.9% as a percentage of revenue | – | – |
| Pro forma adjusted operating profit marginnon-GAAP | 29.3% as a percentage of pro forma revenue | – | – |
| Interest incomeGAAP | (5,259) | – | – |
| Pro forma interest incomeGAAP | (5,242) | – | – |
| Interest expenseGAAP | 22,990 | – | – |
| Pro forma interest expenseGAAP | 22,990 | – | – |
| Change in fair value of investmentsGAAP | 5,251 | – | – |
| Pro forma change in fair value of investmentsGAAP | 5,251 | – | – |
| Other expense, netGAAP | 2,803 | – | – |
| Pro forma other expense, netGAAP | 4,003 | – | – |
| Income from continuing operations, before income taxesGAAP | 63,531 | – | – |
| Pro forma income from continuing operations, before income taxesGAAP | 66,694 | – | – |
| Provision for income taxesGAAP | 10,050 | – | – |
| Pro forma provision for income taxesGAAP | 8,214 | – | – |
| Income from continuing operationsGAAP | 53,481 | – | – |
| Pro forma income from continuing operationsGAAP | 58,480 | – | – |
| Loss from discontinued operationsGAAP | (1,661) | – | – |
| Pro forma loss from discontinued operationsGAAP | (1,661) | – | – |
| Net incomeGAAP | $ 51,820 | – | – |
| Pro forma net incomeGAAP | $ 56,819 | – | – |
| Diluted earnings per share, income from continuing operationsGAAP | $ 0.48 | – | – |
| Pro forma diluted earnings per share, income from continuing operationsGAAP | $ 0.52 | – | – |
| Diluted earnings per share, loss from discontinued operationsGAAP | (0.01) | – | – |
| Pro forma diluted earnings per share, loss from discontinued operationsGAAP | (0.01) | – | – |
| Diluted earnings per share, net incomeGAAP | $ 0.47 | – | – |
| Pro forma diluted earnings per share, net incomeGAAP | $ 0.51 | – | – |
| Weighted average diluted shares of common stock outstandingGAAP | 111,629 | – | – |
| Adjusted earnings per share from continuing operationsnon-GAAP | $1.41 | – | – |
| Pro forma adjusted earnings per share from continuing operationsnon-GAAP | $1.41 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Life SciencesPro forma revenue and pro forma organic revenue decreased as compared to the same period a year ago. | $359 million | – | Pro forma revenue decreased 2%; pro forma organic revenue decreased 3% |
| DiagnosticsPro forma revenue and pro forma organic revenue increased as compared to the same period a year ago. | $371 million | – | Pro forma revenue increased 12%; pro forma organic revenue increased 11% |
full year 2026, on a pro forma basis outlook
- Revenue$2.83-$2.86 billion
- NotePro forma organic revenue growth of 4-5%
- NotePro forma adjusted earnings per share of $5.30-$5.40
What drove it
- The Company reported 4% pro forma revenue growth and 3% pro forma organic revenue growth.
- Diagnostics reported pro forma revenue growth of 12% and pro forma organic revenue growth of 11%.
- Pro forma adjusted operating income was $209 million, which includes $16 million of tariff related refunds.
- The Company recently entered into a definitive agreement to divest its Immunodiagnostics business in China.
- The Company raised full year guidance on a pro forma basis only and excludes China IDX.
Concerns
- Life Sciences pro forma revenue decreased 2% and pro forma organic revenue decreased 3%.
- GAAP operating income from continuing operations was $89 million, as compared to $91 million in the same period a year ago, while GAAP operating profit margin was 12.2%, as compared to 12.6%.
- Pro forma adjusted EPS of $1.41 includes approximately $0.11 from tariff related refunds.
- China IDX represented approximately 6% of the Company’s total revenue in fiscal year 2025, and the transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals.
What to watch
- Life Sciences demand following its 2% pro forma revenue decline and 3% pro forma organic revenue decline.
- Diagnostics growth and adjusted operating profit margin, which was 30.4% as compared to 25.2% in the same period a year ago.
- Execution and timing of the China IDX divestiture, which is expected to close by the end of 2027.
- Delivery against full-year pro forma revenue guidance of $2.83-$2.86 billion, pro forma organic revenue growth guidance of 4-5%, and pro forma adjusted EPS guidance of $5.30-$5.40.
- The effect of tariff-related refunds and the planned use of a portion of recently received refunds to increase investments across the business.
Analysis
Revvity reported second-quarter revenue of $730 million, compared with $720 million in the same period a year ago. On the pro forma basis that excludes China IDX, revenue was $711 million versus $681 million, with 4% pro forma revenue growth and 3% pro forma organic revenue growth. Management cited encouraging signs of increased demand across its customer base and clear momentum in end markets.
Diagnostics was the principal reported growth area. Segment revenue was $371 million versus $354 million, while pro forma revenue increased 12% and pro forma organic revenue increased 11%. Diagnostics adjusted operating income increased to $113 million from $89 million, and adjusted operating profit margin expanded to 30.4% from 25.2%. Life Sciences revenue was $359 million versus $366 million; its pro forma revenue decreased 2% and pro forma organic revenue decreased 3%. Life Sciences adjusted operating income was $112 million versus $115 million, and its adjusted operating profit margin was 31.1% versus 31.6%.
Reported GAAP operating income from continuing operations was $89 million, compared with $91 million, and GAAP operating profit margin was 12.2% compared with 12.6%. The company stated that GAAP operating income included $16 million of tariff related refunds. Adjusted operating income increased to $211 million from $192 million and adjusted operating profit margin increased to 28.9% from 26.6%. On a pro forma adjusted basis, operating income was $209 million versus $180 million and margin was 29.3% versus 26.5%; this operating income included $16 million of tariff related refunds. Pro forma adjusted EPS was $1.41 versus $1.15 and included approximately $0.11 from tariff related refunds.
The company entered into a definitive agreement to divest China IDX, which represented approximately 6% of total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals. Revvity will provide forward-looking guidance on a pro forma basis only, excluding China IDX. It forecast full-year pro forma revenue of $2.83-$2.86 billion, pro forma organic revenue growth of 4-5%, and pro forma adjusted EPS of $5.30-$5.40.
The release characterizes the outlook as raised, but no prior outlook was supplied for comparison. The key reported tension is between strong Diagnostics growth and lower Life Sciences pro forma revenue, alongside GAAP margin pressure and elevated adjusted profitability supported in part by tariff-related refunds. Management said it will use a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth.
Management, verbatim
Revvity delivered a strong second quarter, with results above our expectations and encouraging signs of increased demand across our customer base.
Prahlad Singh, president and chief executive officer of Revvity
As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth.
Prahlad Singh, president and chief executive officer of Revvity
Not in the filing
stated, not guessed- Prior guidance/outlook was not provided, so comparison of actual results versus prior guidance is unavailable.
- Gross profit and gross margin were not reported as standalone line items.
- Full condensed consolidated balance sheet, cash balance, debt balance, operating cash flow, free cash flow, capital expenditures, share repurchases, and dividends were not provided in the supplied filing text.
- The supplied filing text is truncated at the beginning of additional supplemental information, so any subsequent non-GAAP reconciliation details are unavailable.
- Prior-quarter comparisons were not reported for the presented key metrics.
- Segment GAAP operating income was not reported.
- Guidance for gross margin, operating expenses, and tax rate was not reported.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Revvity filed an SEC 8-K (Item 2.02) with a Q2 2026 results press release and provided full-year 2026 pro forma guidance. The release also states it entered a definitive agreement to divest its China Immunodiagnostics business (China IDX).
Ticker impact
Revvity reported Q2 results and raised full-year 2026 pro forma guidance, while also announcing a definitive agreement to divest its China Immunodiagnostics business.
Likely positive bias on guidance raise, with additional volatility around details/assumptions of the China IDX divestiture and its impact on reported versus pro forma metrics.
The filing discloses both a guidance change (actionable for positioning) and a definitive divestiture agreement (material strategic overhang), but it provides limited detail on proceeds, timing mechanics beyond expected close by end-2027, and how guidance is adjusted for the divestiture.
Market effects
Diagnostics and life-sciences tools peers may see read-across on demand momentum and margin resilience, but the China divestiture is company-specific.
China exposure is reduced for Revvity over time, potentially shifting competitive dynamics in China immunodiagnostics.
Tariff-related refunds are cited as a contributor to pro forma results, which could influence sentiment around cross-border supply chains for the sector.
Counterpoint
Raised pro forma guidance may be partly supported by tariff-related refunds and pro forma adjustments that exclude China IDX, so underlying demand durability could be less strong than headline numbers imply.
Key entities
- companyRevvity, Inc.
NYSE-listed life sciences and diagnostics company reporting Q2 2026 results, raising full-year 2026 pro forma guidance, and agreeing to divest China Immunodiagnostics (China IDX).
- business_unitChina Immunodiagnostics business (China IDX)
Immunodiagnostics business in China representing about 6% of fiscal 2025 revenue, expected to close by end-2027 subject to approvals.
